Key TakeawaysBaxter shares slid after the company agreed to sell its kidney care division to Carlyle for $3.8 billion in cash.The company plans to use the roughly $3 billion in after-tax proceeds to reduce its debt.Carlyle's investment is being made through a partnership with Atmas Health. Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash. The deal is expected to generate roughly $3 billion ...

Pitchayanan Kongkaew/iStock via Getty Images Introduction 10 months ago, we had advised investors not to get too myopic about the consequences of the early termination of Novo Nordisk’s (NVO) kidney outcome FLOW trial on Baxter International (NYSE:BAX), but rather focus on some of the more favorable tailwinds surrounding the latter. The BAX stock has since continued to coast along just fine and gauging some of the key highlights from the Q2 results which came out yesterday, we feel even more enthused abo ...

Core Insights - Baxter International Inc. reported second-quarter 2024 adjusted EPS of 68 cents, exceeding the Zacks Consensus Estimate of 66 cents by 3% and showing a year-over-year improvement of 23.6% [1] - The company's revenues from continuing operations reached $3.81 billion, reflecting a 3% increase on a reported basis and a 4% increase at constant currency, surpassing the Zacks Consensus Estimate by 1.9% [2] Revenue Details - Revenue growth was driven by positive demand and pricing across various product categories, with shares of Baxter rising 3.9% in pre-market trading following the results [2] - Year-to-date, Baxter's shares have declined by 10.3%, contrasting with the industry's growth of 3.2% and the S&P 500 Index's increase of 9% [2] Segmental Performance - Medical Products & Therapies segment reported total sales of $1.32 billion, up 4% year over year, benefiting from strong demand and pricing, particularly from the Novum IQ infusion pump [3] - Infusion Therapies & Technologies sales were $1.05 billion, up 4% year over year, while Advanced Surgery sales reached $277 million, up 2% [4] - Healthcare Systems and Technologies segment sales totaled $748 million, up 1% year over year, with growth driven by Care & Connectivity Solutions products [5] - Pharmaceuticals segment sales were $602 million, up 9% year over year, primarily due to new product launches and strong demand for Drug Compounding services [6] - Kidney Care segment sales were $1.12 billion, flat year over year but up 3% at constant currency, with plans to spin off this segment into a separate publicly traded company [7] Margin Analysis - Adjusted gross profit was $1.57 billion, a 4.7% increase year over year, with an adjusted gross margin improvement of 70 basis points to 41.2% [8] - Adjusted operating income from continuing operations was $522 million, up 6.7% year over year, with an adjusted operating margin improvement of 50 basis points to 13.7% [8] Future Guidance - For third-quarter 2024, Baxter anticipates sales growth of 3-4% on a reported basis and 4-5% at constant currency, with adjusted EPS expected between 77 cents and 79 cents [9] - For full-year 2024, sales growth is projected at 3% on a reported basis, with adjusted EPS expected in the range of $2.93-$3.01, an increase from previous guidance [10]

Baxter International Inc. (NYSE:BAX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Mat ...

For the quarter ended June 2024, Baxter International (BAX) reported revenue of $3.81 billion, up 2.8% over the same period last year. EPS came in at $0.68, compared to $0.55 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.74 billion, representing a surprise of +1.80%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

Baxter International (BAX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.03%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.61 per share when it actually produced earnings of $0.65, delivering a surprise of 6.56%.Over the last fou ...

SECOND-QUARTER 2024 EARNINGS Baxter International Inc. August 6, 2024 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements concerning the company's financial results (including the outlook for third-quarter and full-year 2024) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 BAXTER INTERNATIONAL INC. FORM 10-Q For the quarterly period ended June 30, 2024 TABLE OF CONTENTS | | | Page Number | | --- | --- ...

BAXTER REPORTS SECOND-QUARTER 2024 RESULTS DEERFIELD, Ill., AUG. 6, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2024. "Baxter's strategic transformation continues to gain momentum and drive performance benefiting our broad range of stakeholders," said José (Joe) E. Almeida, chair, president and chief executive officer. "In addition to delivering positive top-line and bottom-line results in Q2 2024, Baxter's portfolio of medically ess ...

For Immediate ReleasesChicago, IL – August 6, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baxter International (BAX) , Henry Schein (HSIC) , and IDEXX Laboratories (IDXX) .Here are highlights from Tuesday’s Analyst Blog:What's in Store for These 3 MedTech Stocks in Q2 Earnings?Medical sector players that have ...